What are the potential long-term economic and business effects of the massive protests sweeping Hong Kong?
Both the NFL and its adversaries pointed to the low number of blacked-out games as a reason the FCC should rule in their favor in a dispute over a regulation giving the league the power to punish fans for staying home
The U.S. has precisely the kind of robust infrastructure missing in West African countries struggling to contain the outbreak
Microsoft has given in to critics and brought back the traditional start menu that consumers will recognize from Windows 7
Gross’s success also coincided with one of the best times in history to be a bond investor
Inspired by sculptor Richard Serra, a New Jersey management consultant makes equipment that doesn't dictate how kids play
There are already kimchi and yogurt doughnuts available abroad, but Dunkin' Donuts' top chef sees fermentation coming to the U.S. menu in sandwiches
MBA students from top business schools traveled to the Italian riviera to network with each other in fancy boats last weekend.
Governor Jerry Brown vetoes a union-backed California bill to give franchisees more rights in fights with corporate partners
Founders: Dr. Samir Patel and Dr. David Guyer
VC Investment over the last four quarters: $37.47 million
Founded in 2007, the 15-employee Ophthotech is a biotech company developing treatments for age-related macular degeneration, a common cause of vision loss in older adults. The co-founders' prior venture, Eyetech, was acquired by OSI Pharmaceuticals (OSIP) in 2005 in a deal valued at $900 million.
Key to startup success: "[Our] in-depth understanding of the specific specialty pharma space, coupled with an experienced management and venture investors, has been key to our success."